Introduction {#S0001}
============

Defects in the adaptive immune system lead to humoral immune deficiency syndromes and CIDs (combined immunodeficiencies). Combined immunodeficiencies consist of a heterogeneous group of inherited disorders result from different monogenic defects. In recent years, advances in the diagnostic methods helped us in diagnosis of CID patients who presented with early-onset severe infections and leaded to selection of appropriate treatment \[[@CIT0001]\]. In 2014, IUIS (International Union of Immunological Societies) Expert Committee on PIDs (primary immunodeficiencies) reported last updated CIDs classification as 29 categories \[[@CIT0002]\]. The most frequent forms of CIDs are associated with genetic defects in development of T and/or B lymphocytes. These defects are classified according to presence or absence T, B and natural killer cells (NK cells) and are categorized as T^--^B^--^NK^--^ CID, T^--^B^--^NK^+^ CID, T^--^B^+^NK^--^ CID and T^--^B^+^NK^+^ CID phenotypes \[[@CIT0003], [@CIT0004]\]. Mutations in well-known genes such as *IL2RG, Artemis, RAG1--2, ADA, CD45, JAK3, IL7RA, CD3 (D,E and Z) XLF/Cernunnos and AK2* result in SCID (severe combined immunodeficiency). For example, while mutations in the *ADA* and *RAG1-2* genes cause T^--^B^--^NK^--^ SCID and T^--^B^--^NK^+^ SCID phenotypes, defects in the *JAK3* and *IL7RA* genes lead to T^--^B^+^NK^--^ SCID and T^--^B^+^NK^+^ SCID phenotypes, respectively \[[@CIT0004], [@CIT0005]\]. According to the newborn screening programs, overall incidence of SCIDs is considered to be as 1/50,000--100,000 live births \[[@CIT0004], [@CIT0006]\]. Classic SCID patients are characterized by recurrent, severe or opportunistic infections such as *Pneumocystis jiroveci, Cytomegalovirus* and *Mycobacterial* infections, chronic diarrhea, recurrent oral thrush, and FTT (failure to thrive). In addition to the classic SCID patients, some of SCID forms which are called Omenn syndrome and leaky/atypical SCID result from hypomorphic mutations in SCID associated genes. Other CIDs with dysfunctional T-lymphocytes are associated with mutations in some other genes such as *PNP, ZAP70, MAGT1* and *DOCK8*. These patients can be presented with different clinical manifestations such as autoimmunity, inflammatory disease, lymphoproliferation, and had increased risk of malignancies \[[@CIT0002], [@CIT0004], [@CIT0005], [@CIT0007]--[@CIT0010]\]. In this retrospective study, we report clinical presentations and molecular defects of the 40 CID patients at the Pediatric Immunology, Erciyes University Medical Faculty, in Kayseri, Turkey as single center experience.

Material and methods {#S0002}
====================

Patients and diagnostic criteria {#S20003}
--------------------------------

Between 1994 and 2014 years, 40 patients (females: 15, males: 25) from 31 unrelated families were clinically diagnosed as CID. The diagnosis of CIDs was based on PAGID (Pan American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) diagnostic criteria \[[@CIT0011]\]. The definitive diagnosis of CIDs was performed with genetic confirmation in the causative genes. The normal values of lymphocyte subsets and immunoglobulins were based on previously described in the medical literature for Turkish children \[[@CIT0012], [@CIT0013]\]. This retrospective study was approved by Erciyes University Medical Faculty Ethics Committee. Also, signed consent form was obtained from parents.

Immunological investigations {#S20004}
----------------------------

The concentrations of Ig (immunoglobulin) G, IgA and IgM were determined with nephelometric method. T-cell subsets, B-cells and NK-cells were evaluated with flow cytometry using monoclonal antibodies (CD3, CD4, CD8, CD19, CD16/56; Becton Dickinson, San Jose, USA). The proliferation functions of T-cells were evaluated with using PHA (Phytohemagglutinin) as *in vitro*. When the PHA proliferation responses less than 10% of control it was accepted as decreased. Activity of ADA (adenosine deaminase) and PNP (purine nucleoside phosphorylase) enzymes were evaluated by tandem mass spectrometric screening with elevated level of ADA or PNP substrates \[[@CIT0014]\]. The phenotypic classification of CID patients was performed based on absolute count of peripheral T^--^, B^--^ and NK-cells.

Molecular diagnosis {#S20005}
-------------------

Molecular tests to detect mutations in known CID associated genes were performed in two specialized laboratories on PIDs \[(Erasmus MC, in Rotterdam, Netherland and Duke University, Durham City in North Carolina, United States of America (USA)\]. According to the clinical manifestations, immunologic evaluations, and phenotypic groups of CID patients, mutations in known CID associated genes were sequenced \[[@CIT0015]\].

Results {#S0006}
=======

Demographic data {#S20007}
----------------

Forty patients were included in this retrospective study ([Table 1](#T0001){ref-type="table"}). The ratio of female/male was 3/5. The median age at the onset of clinical manifestations was 2 months (range: 15 days -- 15 years) while the median age of diagnosis was 4 months (range: 1 month -- 17 years). Parental consanguinity was observed in 32 (80%) of patients. Only 2 patients were referred prior to clinical manifestation due to positive family history (P5, P10). Cumulative, of the 40 CID patients, 26 were lost (including 3 patients who received HSCT) by the end of 2014. The median age of death was 6 months (range, 2.5 months -- 18 years). Most of deaths were observed within 12 months of life (20 of 26 lost patients, 77%). Of the 9 survived patients who did not receive HSCT, the median age was 4 years (range: 9 months -- 17 years).

###### 

Clinical characteristics of patients

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients   Gender   Consanguinity/\   Age of\   Age of\     Genetic\   Infectious\                                        Non-infectious\                                   Outcome                    Age of\
                      Family history    onset     diagnosis   defect     complications                                      complications                                                                death
  ---------- -------- ----------------- --------- ----------- ---------- -------------------------------------------------- ------------------------------------------------- -------------------------- ---------
  P1         male     +/--              1 mo      3.5 mo      ADA        diarrhea, oral thrush                              FTT                                               alive (IVIG + AMP + ERT)   alive

  P2         male     +/+               7 mo      1.5 y       PNP        pneumonia                                          FTT, spastic paraparesis, hypouricemia            alive (HSCT)               alive

  P3         male     +/--              9 mo      2 y         PNP        pneumonia, diarrhea                                hypouricemia                                      died                       1.5 y

  P4         male     +/+               1 mo      2 mo        ADA        pneumonia, diarrhea, sepsis                        hypouricemia                                      died                       8 mo

  P5         female   +/+               15 days   1 mo        ADA        oral thrush, pneumonia                             Hypouricemia                                      died                       2.5 mo

  P6         male     +/--              1.5 mo    3 mo        ADA        diarrhea, pneumonia, sepsis                        hypouricemia, hepatomegaly                        died                       5 mo

  P7         male     +/+               1.5 mo    4 mo        unknown    oral thrush, pneumonia                             FTT, hepatosplenomegaly                           died                       5 mo

  P8         female   +/--              2 mo      3 mo        unknown    pneumonia, diarrhea, sepsis                        FTT, hepatomegaly                                 died                       4 mo

  P9         male     +/--              2 mo      3 mo        ADA        pneumonia, diarrhea, sepsis                        FTT, hypouricemia                                 died                       6 mo

  P10        female   +/+               1.5 mo    2 mo        ADA        oral thrush, CMV pneumonia                         FTT, hepatomegaly, hypouricemia                   alive (HSCT)               alive

  P11        male     --/--             2 mo      5 mo        artemis    oral thrush, pneumonia, TBCitis                    FTT                                               alive (HSCT)               alive

  P12        female   --/--             2 mo      3 mo        unknown    diarrhea, sepsis                                   FTT, microcephaly                                 died                       5 mo

  P13        female   +/--              10 y      15 y        RAG1       URTI, pyoderma gangrenosm                          AHA, pancytopenia, splenomegaly                   alive (IVIG + AMP)         alive

  P14        male     +/--              2 mo      3 mo        unknown    pneumonia, CMV, sepsis                             low set ears, pancytopenia                        died                       4 mo

  P15        female   --/--             1 mo      2 mo        unknown    diarrhea, oral thrush, sepsis                      FTT, hepatomegaly                                 died                       4 mo

  P16        female   +/+               1.5 mo    3 mo        unknown    diarrhea, sepsis                                   hepatomegaly, skin rash                           died                       5 mo

  P17        female   +/--              15 days   2 mo        unknown    oral thrush, pneumonia                             FTT                                               died                       4 mo

  P18        male     +/--              1 mo      3 mo        unknown    pneumonia                                          hepatomegaly                                      died                       5 mo

  P19        male     +/+               3 mo      7 mo        XLF        oral thrush, pneumonia, diarrhea, fungal abscess   FTT, BLF, IUGR, NHL, microcephaly, pancytopenia   alive (IVIG + AMP)         alive

  P20        female   +/--              10 mo     3.5 y       XLF        URTI, diarrhea                                     FTT, BLF, IUGR, microcephaly, pancytopenia        alive (IVIG + AMP)         alive

  P21        female   --/--             1 mo      2.5 mo      unknown    oral thrush, pneumonia                             FTT, hepatomegaly                                 died                       5 mo

  P22        male     +/--              1 mo      3.5 mo      unknown    pneumonia                                          FTT                                               alive (HSCT)               alive

  P23        male     +/--              10 mo     1.5 y       unknown    URTI, diarrhea                                     FTT, AHA                                          alive (IVIG + AMP)         alive

  P24        male     +/+               2 mo      4 mo        unknown    pneumonia                                          FTT, hepatomegaly                                 alive (IVIG + AMP)         alive

  P25        female   +/--              5 mo      7 mo        unknown    pneumonia, diarrhea                                FTT                                               died                       8 mo

  P26        female   +/--              4 mo      12 mo       RAG1       diarrhea, CMV, dermatitis                          FTT, hepatosplenomegaly                           died (HSCT)                1.5 y

  P27        male     +/--              3 mo      5 mo        RAG1       pneumonia, sepsis                                  FTT                                               died (HSCT)                7 mo

  P28        female   +/--              1.5 mo    5 mo        RAG1       pneumonia, diarrhea, lung tbc                      FTT, hepatomegaly                                 died                       7 mo

  P29        male     +/--              2 mo      4 mo        JAK3       pneumonia, diarrhea, sepsis                        FTT, HLH                                          died                       6 mo

  P30        female   +/--              2 mo      3.5 mo      unknown    pneumonia                                          FTT, skin rash                                    died                       6 mo

  P31        male     +/+               3 mo      8 mo        ZAP70      HSV, CMV pneumonia, fungal abscess                 AHA, SBI, CNS, NHL                                died                       15 mo

  P32        male     +/--              6 mo      1.5 y       ZAP70      diarrhea, URTI                                     hepatosplenomegaly                                died                       1.5 y

  P33        female   +/+               3 mo      5 mo        unknown    pneumonia                                          FTT, hepatomegaly                                 died                       7 mo

  P34        male     --/--             3 mo      5 mo        unknown    pneumonia                                          FTT                                               died                       8 mo

  P35        male     --/--             4 mo      6 mo        unknown    oral thrush                                        FTT, hepatomegaly                                 alive (HSCT)               alive

  P36        male     --/--             2 mo      3 mo        IL2RD      pneumonia, CMV, sepsis                             FTT, HLH                                          died                       5 mo

  P37        male     --/--             4 mo      9 mo        unknown    URTI, diarrhea                                     FTT                                               alive (IVIG + AMP)         alive

  P38        male     +/--              2 y       9 y         DOCK8      otitis media                                       aorta aneurism, viral dermatitis                  alive (IVIG + AMP)         alive

  P39        male     +/--              11 mo     2 y         ZAP70      pneumonia, lung TBC, diarrhea                      FTT, SBI, hepatomegaly                            alive (IVIG + AMP)         alive

  P40        male     +/--              15 y      17 y        MAGT1      URTI, CMV, EBV                                     AHA, HL, GBS, AH                                  died (HSCT)                18 y
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AH -- autoimmune hepatitis; AHA -- autoimmune hemolytic anemia; AMP -- antimicrobial prophylaxis; BLF -- bird like face; CMV -- Cytomegalovirus; CNS -- congenital nephrotic syndrome; ERT -- enzyme replacement treatment; FTT -- failure to thrive, GBS -- Guillain-Barré syndrome; HSCT -- hematopoietic stem cell transplantation; HL -- Hodgkin lymphoma; HLH -- hemophagocytic lymphohistiocytosis; HSV -- Herpes simplex virus; IVIG -- intravenous immunoglobulin; IUGR -- intrauterine growth retardation; mo -- month; NHL -- non-Hodgkin lymphoma; URTI -- upper respiratory tract infections; y -- year

Family history {#S20008}
--------------

Of the CID 40 patients, 10 (25%) had a positive family history for suspected or confirmed PIDs. Of the 10 patients (females: 3, males: 7), 6 were confirmed by sequencing including 2 siblings with ADA deficiency (P4 and P5). The positive family history group includes 3, 1, 1, 1 and 4 patients with mutation in the *ADA, PNP, XLF/Cernnunos, ZAP70* genes and unknown molecular diagnosis respectively. Patients with positive family history had died sibling or siblings in their family. All patients in this group had history of parental consanguinity. In this group, 6 mothers were carrier for CIDs.

Presenting symptoms {#S20009}
-------------------

Thirty eight patients displayed clinical symptoms when diagnosed. Only 2 of the CID 40 patients were diagnosed before onset symptoms because of positive family history (P5, P10). However, they had symptoms in their follow-up. The most frequent infection types were respiratory tract infections, chronic diarrhea, and oral thrush. Respiratory tract infections (33/40 cases, 82.5%) were the most common infections with pneumonia (27 cases, 67.75%) and upper respiratory infections (6 cases, 15%). Gastrointestinal infections and oral thrush were observed in 19 (19/40, 47.5%) and in 10 (25%) patients respectively.

Also, multiple infection combinations were observed in follow-up of patients as follows; (10/40, 25%) with combined pneumonia/diarrhea, (17.5%) with combined pneumonia/oral thrush, and 3 (7.5%) with combined diarrhea/oral thrush. Thirteen patients (13/40, 32.5%) had severe infections, including sepsis in 11 (27.5%), fungal infection as abscess formation in 2 (5%) and disseminated tuberculosis in 2 (5%). Disseminated *Cytomegalovirus* infection was observed in 6 (15%) patients. Also, non-infectious symptoms and signs were observed in this study as follows; FTT in 27 (27/40, 67.5%), hepatosplenomegaly in 16 (40%), hypouricemia in 7 (17.5%), autoimmunity in 4 (10%), and pancytopenia in 4 (10%), skin rash in 3 (7.5%), spastic paraparesis in 1 (2.5%), silent brain infarcts in 2 (5%), bird-like face in 2 (5%), intrauterine growth failure in 2 (5%), microcephaly in 2 (5%), congenital nephrotic syndrome in 1 (2.5%), and aorta aneurism in 1 (2.5%). In addition to these data, 3 patients had lymphoproliferative malignancies. Two patients had non-Hodgkin lymphoma (P19, P31) and 1 had Hodgkin lymphoma (P40). Of 27 patients (27/40, 67.5%) with FTT, 13 (32.5%), 7 (17.5%) and 4 (10%) had anemia, hypoalbuminemia and combined anemia/hypoalbuminemia respectively. Of the 40 CID patients, 14 (14/40, 35%) had BCG vaccination prior to diagnosis, 21 patients did not received BCG vaccination, and remaining 5 patients were unclear for BCG vaccination. Three patients had BCG complications, including lung TBC in 2 (P28, P39) and BCG it is in 1 (P11).

Immunological characteristics {#S20010}
-----------------------------

Immunological data were showed in [Table 2](#T0002){ref-type="table"}. Thirty six (90%) patients had lymphopenia with decreased absolute lymphocyte counts (ALC) (for \< 2 years; \< 3000/mm^3^, for \> 2 years; \< 1500/mm^3^) at the time of diagnosis. Only 4 patients (10%) had normal lymphocyte counts (P31, P32, P39 and P40). Of the CID 40 patients, 36 (90%) and 31 (77.5%) had significantly lower IgA and IgM levels respectively. The IgG levels were significantly lower (\< 300 md/dl) in 21 (52.5%) patients. Some patients had normal or elevated serum IgG concentrations may reflect maternal IG levels at diagnosis of CID. Another 5 patients had also normal or elevated IgG levels with mutation in the *RAG1* gene in 1 (P13), ZAP70 deficiency in 2 (P31, P32), DOCK8 deficiency in 1 (P38), and mutation in the *MAGT1* gene in 1 (P40). Serum IgE levels were elevated in 3 patients with mutation in the *JAK3* (P29), *RAG1* (P26) and *DOCK8* (P38) genes, respectively (data not shown). The lymphocyte proliferative responses with PHA stimulation were absent or significantly decreased in all presented patients. Patients dived to 4 phenotypic groups based on T^--^, B^--^ and NK-cells as follows; T^--^B^--^NK^--^ CID, T^--^B^--^NK^+^ CID, T^--^B^+^NK^--^ CID and T^--^B^+^NK^+^ CID. Of the 40 CID patients, 14, 15, 9 and 2 had T^--^B^--^NK^--^ CID, T^--^B^--^NK^+^ CID, T^--^B^+^NK^--^ CID and T^--^B^+^NK^+^ CID phenotypes respectively. Of the 14 T^--^B^--^NK^--^ CIDs, 6, 2 (siblings), 1 and 4 had a mutation in the *ADA, PNP, Artemis, RAG1* genes and unknown genetic diagnosis respectively. Of the 15 T^--^B^--^NK^+^ CIDs, 3, 2 (siblings) and 10 had a mutation in the *RAG1, XLF/Cernunnos* genes and unknown genetic diagnosis respectively. Of the 9 T^--^B^+^NK^--^ CIDs, 2 siblings, 1, 1 and 5 had a mutation in the *ZAP70, IL2RG, DOCK8* and unknown genetic diagnosis respectively. Of the 2 T^--^B^+^NK^+^ CIDs, 2 had a mutation in the *MAGT1* and *ZAP70* genes respectively.

###### 

Immunological and genetic data of patients

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients               Genetic defect       Mutations                                            ALC\      CD3\      CD19\     NK\       IgG\      IgA\      IgM\
                                                                                                   (mm^3^)   (mm^3^)   (mm^3^)   (mm^3^)   (mg/dl)   (mg/dl)   (mg/dl)
  ---------------------- -------------------- ---------------------------------------------------- --------- --------- --------- --------- --------- --------- ---------
  **T^--^B^--^NK^--^**   **T^--^B^--^CIDs**                                                                                                                    

  P1                     ADA                  del \[GAAGA\] c.955-959                              210       102       48        64        342       6.2       15.3

  P2                     PNP                  (c.700 C \> T, p.R234X)                              320       110       150       58        342       17.6      66.9

  P3                     PNP                  (c.700 C \> T, p.R234X)                              380       206       80        98        450       12.5      34

  P4                     ADA                  (c.736C \> T, p.Q246X)                               230       60        96        75        310       5.3       16.9

  P5                     ADA                  (c.736C \> T, p.Q246X)                               520       286       150       88        420       6.1       17.3

  P6                     ADA                  (c.736C \> T, p.Q246X)                               430       214       78        144       110       6.6       5.6

  P7                     unknown              unknown                                              520       352       94        72        230       6.2       12.8

  P8                     unknown              unknown                                              410       240       89        80        324       6.1       17.3

  P9                     ADA                  (c.736C \> T, p.Q246X)                               350       213       96        42        72.7      4.7       6.6

  P10                    ADA                  (c.736C \> T, p.Q246X)                               230       40        112       78        254       6.2       7.9

  P11                    artemis              biallelic homozygous deletion in the first 3 exons   120       34        50        38        156       6.7       9.4

  P12                    unknown              unknown                                              530       218       180       130       150       29        40

  P13                    RAG1                 (c.2290C \> T, p.Arg764Cys)                          750       412       184       158       2900      903       71

  P14                    unknown              unknown                                              100       20        18        60        39        5.7       17

  **T^--^B^--^NK^+^**                                                                                                                                          

  P15                    unknown              unknown                                              840       468       89        262       148       8.1       12.7

  P16                    unknown              unknown                                              480       203       48        230       130       5.8       7.8

  P17                    unknown              unknown                                              1800      597       216       984       252       6.7       18.2

  P18                    unknown              unknown                                              600       197       98        312       253       7.8       4.1

  P19                    XLF                  (c.622C \> T, p.R178X)                               1950      543       201       1210      784       60        190

  P20                    XLF                  (c.622C \> T, p.R178X)                               1070      300       253       526       134       6.2       138

  P21                    unknown              unknown                                              700       263       98        434       160       13        8

  P22                    unknown              unknown                                              950       321       198       428       168       8.6       10.2

  P23                    unknown              unknown                                              690       112       248       341       377       6.7       34

  P24                    unknown              unknown                                              780       284       279       288       378       8.2       24

  P25                    unknown              unknown                                              1950      510       253       1183      145       6.3       22.6

  P26                    RAG1                 (c.1229 G \> A, p.Arg410Gln)                         1770      516       378       866       134       6.5       18

  P27                    RAG1                 (c.1767C \> G, p.Tyr589Stp)                          440       120       58        243       298       6.1       17.5

  P28                    RAG1                 (c.2209C \> T, p.Arg737Cys)                          630       125       137       371       210       6.4       17.1

  P29                    JAK3                 c.2324G \> A                                         1660      598       297       775       320       24        106

  **T^--^B^+^NK^--^**    **T^--^B^+^ CIDs**                                                                                                                    

  P30                    unknown              unknown                                              920       252       580       88        137       6.1       20.8

  P31                    ZAP70                (c.1193C \> T, p.IIe398Ser)                          4700      1680      2870      142       1680      38        114

  P32                    ZAP70                (c.1193C \> T, p.IIe398Ser)                          3200      1425      1626      139       890       27        81

  P33                    unknown              unknown                                              800       137       547       117       416       6.2       28

  P34                    unknown              unknown                                              850       171       552       124       154       4.2       12.7

  P35                    unknown              unknown                                              1210      160       743       118       69        7         6.5

  P36                    IL2RD                c.595-1G \> T                                        890       240       524       135       145       6.5       17.3

  P37                    unknown              unknown                                              1060      214       712       132       318       25        43

  P38                    DOCK8                large homozygous deletion between exon 18 and 48     1200      720       250       180       1600      120       79

  **T^--^B^+^NK^+^**                                                                                                                                           

  P39                    ZAP70                (c.1504_1505insGC, p.Pro502ArgfsX43)                 3460      472       2310      696       1060      152       210

  P40                    MAGT1                (c.555dup, p.Tyr186Ilefs\*2)                         1560      502       898       256       880       50        52
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADA -- adenosine deaminase; ALC -- absolute lymphocyte count; CIDs -- combined immunodeficiencies; DOCK8 -- dedicator of cytokinesis 8; IgA -- immunoglobulin A; IgG -- immunoglobulin G; IgM -- immunoglobulin M; JAK3 -- Janus kinase 3; MAGT1 -- magnesium transporter 1; NK -- natural killer cell; PNP -- purine nucleoside phosphorylase; RAG1 -- recombination-activating gene 1; ZAP70 -- zeta-chain associated protein 70 kDa; XLF -- XRCC4-like factor

Outcomes and hematopoietic stem cell transplantation {#S20011}
----------------------------------------------------

Overall survival of patients was estimated as 35% (14 of the CID 40 patients) in this study. Of 32 patients who did not receive HSCT, 17 died soon after diagnosis (range: 15 days -- 3 months) whilst 3 survived longer than 6 months with PNP deficiency in 1 (P3) and ZAP70 deficiency in 2 siblings (P31, P32). The cause of deaths was severe infections in all patients as follows; sepsis in 10, severe pneumonia in 4, and disseminated BCG in 1.

Of the CID 40 patients, only 8 (8/40, 20%) received HSCT by the end of 2014. Of the 8 transplanted patients, 6 received reduced intensity conditioning (RIC) regimen (anti-thymocyte globulin-based protocols with rituximab, fludarabine, thiotepa, etoposide and melphalan) and 2 (P26, P40) received myeloablative conditioning (MAT) regimen (busulfan plus cyclophosphamide based protocols). Two transplanted patients (P1, P40) experienced graft versus host disease (GVHD). GVHD was observed in the gut and skin as Stage 4 and Stage 3 in P1 and P40 respectively. Procedure was successful in 5 (P2, P10, P11, P22 and P35) patients, leading to full immune reconstitution and survival in 4 patients, IVIG replacement is needed in 1 patient. Two patients (P26, P27) died due to infectious complications after then post-transplant 6^th^ month and 1 patient (P40) died due to early post-transplant complication (intracranial hemorrhage).

Discussion {#S0012}
==========

CIDs should be thought in children who experienced early onset severe infections, recurrent oral thrush, manifestations of immune dysregulation, malignancy, chronic diarrhea, FTT, and BCG infections \[[@CIT0016]\]. The SCID patients present with severe infections in the first months of life. In this study, the types of infections were consistent with previously published case series in the medical literature with the most common respiratory tract infections \[[@CIT0005], [@CIT0017]\]. When considering data associated with CIDs, the onset age of symptoms in patients with CID can be more heterogeneous. Especially, the onset of symptoms in some CID associated genes such as *IL2RG*, *JAK3, RAG1/2, ADA* defects can be significant heterogeneous from infancy to adulthood \[[@CIT0017], [@CIT0018]\]. In this study, we observed also symptom onset heterogeneities in the CID patients. The median age at the onset of infections was 2 months. However, the onset of symptoms was observed in the 4 CID patients after the first year (P13, P20, P38 and P40). In the presented study, the median age of diagnosis was 4 months (range: 15 days -- 15 years). For the median age of diagnosis, when we compared our results with previously published studies, our data were consistent with 5 months in 44 patients in China, 6.2 months 30 patients in Greece, and 4.6 months in patients in France \[[@CIT0017], [@CIT0019], [@CIT0020]\]. Severe infections such as pneumonia, sepsis and *Cytomegalovirus* infections are important mortality and morbidity reasons in the CID patients. In addition to the severe infections, FTT is another significant common symptom in patients with CID patients, especially in the SCID patients. Of the 40 CID patients, 27 (67.5%) had FTT. Although the ratio of FTT was higher than in some published studies with approximately 45% in Serbia/Montenegro and 38.64% in China, lower than in other reported studies with 88% that in United Kingdom and 100% in Egypt \[[@CIT0005], [@CIT0017], [@CIT0021]\]. Also, BCG infections either localized or disseminated after vaccination are important mortality and morbidity reasons in patients with CID patients, especially in the SCID patients \[[@CIT0008], [@CIT0017]\]. In this study, 14 had BCG vaccination prior to diagnosis. Of the 14 vaccinated patients, 3 (21.3%) had BCG infections (2 had lung BCG infection as disseminated and 1 had localized infection). This ratio of BCG infections was significantly lower than that in Brazil with 65% and China with 41.18% \[[@CIT0008], [@CIT0017]\]. These differences in the BCG infections may result from the preventive health care policies in these countries. Also, lymphopenia is one of the most important findings in patients with CID, especially in the SCID patients \[[@CIT0005], [@CIT0007], [@CIT0017]\]. In the presented study, of 40 patients, 36 (90%) had lymphopenia. Lymphopenia was reported as 90% by Gossage *et al*. \[[@CIT0022]\] which was consistent with our data. Also, lymphopenia was reported as approximately 60% in the CID patients in a previously published study in Turkey. In addition to lymphopenia, some patients with CID may have normal or elevated ALC \[[@CIT0001]\]. In this study, only 4 (P31, P32, P39 and P40) patients had normal ALC according to the aged normal values \[[@CIT0012]\]. Excluding detection of immunoglobulins, subgroups of lymphocytes and lymphocyte proliferative responses other specific immunological tests such as sequencing have not been performed in Turkey for all known CID genes. So, we are having difficulty in diagnosis of patients with CID especially in patients with normal or elevated ALC in Turkey.

In this study, sequencing showed interesting genetic results. Although the X linked CIDs were reported as a most common group with approximately 45% among the CID groups, only 1 patient (2.5%) had a mutation the IL2GR gene in the presented study \[[@CIT0020], [@CIT0023], [@CIT0024]\]. As the nearest ratio of X linked patients in the CID patients was reported as 14% in Serbia and Montenegro and approximately 9% in Greece \[[@CIT0005], [@CIT0019]\].

In the 29 T^--^B^--^ CID phenotypic patients, 6 (6/40, 15%), 4 (10%), 2 (5%), 2 (5%, siblings), 1 (2.5%), 1 (2.5%) and 13 (32.5%) had a mutation in the *ADA, RAG1, PNP, XLF/Cernnunos, Artemis, JAK3* genes and 13 unknown genetic defect respectively. The ADA deficiency was reported as 9.4% in the SCID patients by Stephan *et al*. \[[@CIT0020]\]. Also, Buckley *et al*. \[[@CIT0023]\] reported ADA deficiency as 14.8% which was consistent with our results. Mutations in the *RAG1/2* genes represent approximately 6-10% of all CID and 25% of atypical SCID cases \[[@CIT0001]\]. In this study, we had 4 patients (4/40, 10%) with RAG1 deficiency. Of the 4 RAG1 defects, 1 (P13) had atypical presentation with pyoderma gangrenosum as leaky/atypical SCID.

Of the 11 T^--^B^+^ CID patients, 3 (3/40, 7.5%), 1 (2.5%), 1 (2.5%), 1 (2.5%) and 5 had a mutation in the *ZAP70, IL2RD, DOCK8, MAGT1* genes and unknown genetic defect respectively. Three patients (P31, P32 and P39) had ZAP70 deficiency in this study. Two of them (P31, P39) had silent brain infarcts as a common feature \[[@CIT0025]\]. All patients with ZAP70 deficiency had SCID presentation with severe infection in their first year of life. The DOCK8 deficiency was found in 1 patient (P38) in the presented study. The patient presented with recurrent dermatitis and had a giant aortic aneurism.

In this study, symptoms were observed (P13, P38 and P40) after age of 1 year in 3 patients with mutations in the *RAG1, DOCK8* and *MAGT1* genes respectively. These patients did not meet the SCID criteria. MAGT1 deficiency has been reported in 10 patients in the medical literature so far. Our patient with MAGT1 deficiency (P40, called as XMEN syndrome) presented with severe autoimmunity and also had a novel mutation \[[@CIT0026]\].

The overall risk of developing malignancy in children with PIDs is 4-25% \[[@CIT0027]\]. Of the 40 CID patients, 3 had (3/40, 7.5%) malignancies. Two patients had (P19 and P31) diffuse large B cell lymphoma in the brain and in the liver in patients with XLF and ZAP70 deficiency respectively \[[@CIT0028]\]. Another malignancy, Hodgkin lymphoma was observed in the MAGT1 deficient patient (P40) in this study \[[@CIT0029]\].

Irrespective of genetic diagnosis, HSCT is the main curative treatment in patients with SCID. However, only 8 patients received HSCT in this study. Majority of patients died due to severe infections prior to HSCT. In contrast to our data, in France, of the 117 SCID patients, 95 received HSCT between 1970 and 1991, 166 patients received HSCT in almost last 28 years by the end of 2010 in USA \[[@CIT0007], [@CIT0030]\]. Of the 8 transplanted patients, 5 survived by the end of 2014. In this study, although the transplantation rate was much more lower than in France and USA \[[@CIT0007], [@CIT0030]\], higher than in China \[[@CIT0017]\]. Also, although survival rate much lower than in France and USA \[[@CIT0007], [@CIT0030]\] higher than in China \[[@CIT0017]\]. Most SCID patients cannot be diagnosed early enough and the most patients miss the window opportunity of transplantation prior to the development of severe infection. We can speculate that delayed diagnosis and active infections before transplantation can be principle reasons in lower rate of transplantation and survival in Turkey as in observed other developing countries.

In conclusion, there is no national registry center in Turkey for CIDs yet. Also, we can say that CIDs are more common in Turkey than in the developed countries due to high rate of consanguinity \[[@CIT0001]\]. With this study, it has been confirmed once again CID is a pediatric emergency condition with high mortality rate (65%) in Turkey. Also, we can conclude that the patients presented with severe infections onset in the first months of life have to be examined for CIDs. In addition, leaky/atypical SCID should be considered in patients presented with atypical and late-onset of symptoms such as observed in P13, P38 and P40. In recent years, patients with CID have good opportunities with improvement in supportive care and conditioning protocols for HSCT as curative treatment. In these patients, diagnosis can be performed at the early age, infective mortalities/morbidities can be minimized and HSCT can be performed at the early ages. For early diagnosis, the awareness programs should be performed in Turkey for physicians. Also, new diagnostic methods such as whole exome/genome sequencing (WES/WGS) should be used in order to enhance the quality of diagnosis in Turkey. Also, population-based newborn screening programs with tandem mass spectrometry and/or T-cell receptor excision circles (TRECs) should be considered as general health policy for patients with CIDs and national practical treatment protocols should be established in Turkey.
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